Clinical trials
T-cell Leukemia clinical trials
Below are recruiting t-cell leukemia clinical trials, each written for real people, not researchers. We’re tracking 189 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06059391RecruitingPhase 2
Vaccine for stem cell donors to prevent CMV
This trial tests whether giving a CMV vaccine to stem cell donors can help protect recipients from CMV infection after transplant. It is for adults with specific blood cancers who are CMV-positive and have a matched related donor.
Duarte, CaliforniaAges 18–75 - NCT06013423RecruitingPhase 2
Cord blood transplant with chemo and radiation for high-risk blood cancers
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
Seattle, WashingtonAges 6 months–65 years - NCT07556757RecruitingPhase 1
CD-19 T-cell therapy for relapsed B-cell leukemia in teens and adults
This study tests a new engineered cell therapy (CD-19 t-haNK) designed to fight back B-cell acute lymphoblastic leukemia (a blood cancer) in patients whose cancer has returned or stopped responding to standard treatment. The therapy uses specially modified immune cells to target and destroy leukemia cells.
JohannesburgAges 12 years+ - NCT05621291Recruiting
Sequencing test to guide care after CD19 CAR T in kids
This study checks a DNA-based lab test (next-generation sequencing, or NGS) to monitor B-cell recovery after CD19 CAR T treatment in children and young adults. The goal is to see whether the test can help guide management while looking for remission and safe recovery.
Los Angeles, CaliforniaAges 1–25 - NCT01853631RecruitingPhase 1
CAR T-cell therapy for CD19-positive B-cell blood cancers
This Phase 1 study tests a personalized form of immune therapy called CAR T cells that are designed to recognize CD19, a marker on certain B-cell cancers. It may help people with difficult-to-treat (recurrent or relapsed) B-cell lymphoma or leukemia (ALL/CLL).
Houston, TexasAges Up to 75 years - NCT04662294RecruitingEarly Phase 1
CD70-targeted CAR T therapy for CD70-positive blood cancers
This trial tests a customized immune-cell treatment (CAR T) that targets CD70 on cancer cells in certain blood cancers. It may help people whose disease has returned or did not respond to standard treatments.
Hangzhou, ZhejiangAges Any age - NCT07645469RecruitingPhase 1
WT1 T Cell Therapy With Azacitidine for AML Minimal Residual Disease
This trial tests a new type of immune therapy using your own T cells (white blood cells) that are trained to fight AML cancer cells. It's designed for patients whose AML has mostly gone away with chemotherapy but still has traces of cancer detectable in blood or bone marrow tests.
Seattle, WashingtonAges 18 years+ - NCT07575919RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Standard-Risk B-ALL After Chemotherapy
This trial tests a new type of immunotherapy called CAR-T cells to help prevent relapse in adults with B-cell acute lymphoblastic leukemia (a blood cancer) who have responded well to standard chemotherapy. The treatment is designed as a consolidation therapy to strengthen remission after initial chemotherapy.
Beijing, Beijing MunicipalityAges 18–85 - NCT06343311RecruitingPhase 1/Phase 2
T-cell therapy for adults with relapsed or refractory B-cell lymphoma
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
Sacramento, CaliforniaAges 18 years+ - NCT06220487RecruitingPhase 2
New drug combo for Ph+ ALL without transplant
This trial tests a combination of three drugs—olverembatinib, a bispecific T-cell engager, and chidamide—for adults newly diagnosed with Ph+ ALL who cannot have a stem cell transplant. The goal is to see if this treatment works well without needing intensive chemotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT05773040RecruitingPhase 1
CAR T-cell therapy made from your own immune cells
This Phase 1 trial tests an “autologous” CAR T-cell treatment (made from your own T cells) that targets a cancer marker called CD79b in certain relapsed or hard-to-treat B-cell lymphomas. It’s designed to find a safe dose and see whether the treatment can shrink tumors and help control the lymphoma after prior therapies.
Houston, TexasAges 18 years+ - NCT07259070RecruitingPhase 1/Phase 2
CAR T-cells targeting BAFF-R for resistant B-cell lymphoma
This trial tests a new kind of immunotherapy called CAR T-cells that are designed to find and attack a protein called BAFF-R on your lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded well to at least two earlier treatments.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06137118RecruitingPhase 1/Phase 2
AZD0486 for B-cell acute lymphoblastic leukemia
This trial tests a new drug called AZD0486 for people with a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. It aims to see if the drug can help control the cancer.
Birmingham, AlabamaAges 12 years+ - NCT05626400Recruiting
CAR T for relapsed T-ALL or T-LBL with CD7
This trial tests a type of immune therapy (CAR T cells) called Senl-T7 in people whose T-cell leukemia or lymphoma has come back or did not respond. It aims to target cancer cells that carry a marker called CD7.
Beijingcun, HebeiAges 2–70 - NCT06909474RecruitingPhase 1
CD5-targeted CAR-NK therapy for relapsed T-cell blood cancers
This trial tests a new therapy using your own immune cells (NK cells) engineered to find and kill cancer cells that carry the CD5 protein. It is for people with T-cell acute lymphoblastic leukemia or certain T-cell lymphomas that have not responded to treatment or have returned.
Wuhan, HubeiAges 18–75 - NCT05011422RecruitingPhase 1
Haploidentical stem cell transplant for high-risk leukemia in children
This early-phase study tests a transplant using a “partially matched” (haploidentical) donor’s stem cells, with extra lab steps to reduce certain immune cells. It is designed for children with high-risk blood cancers to lower relapse risk and improve outcomes.
St Louis, MissouriAges Up to 30 years - NCT06326463RecruitingPhase 1
CAR T-cell therapy for CD70-positive blood cancers in children
This trial tests a special immune cell therapy (CAR T-cells) that targets a protein called CD70 on blood cancer cells. It is for children and young adults up to age 21 whose cancer has come back or hasn't gotten better with other treatments.
Memphis, TennesseeAges Up to 21 years - NCT06285825RecruitingPhase 2
Study of emapalumab for low blood counts after CAR T-cell therapy
This study tests a drug called emapalumab to help people whose blood counts stay low for weeks after CAR T-cell therapy for certain types of lymphoma. The goal is to see if the drug can help the body recover normal blood cell production.
Houston, TexasAges 18 years+ - NCT06733051RecruitingPhase 2
Study of Golidocitinib and Benmelstobart for relapsed ENKTL lymphoma
This trial tests a new drug combination for people with a rare type of lymphoma (ENKTL) that has come back or not responded after prior treatment. It aims to see if the combination can help control the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06066346RecruitingPhase 2
Talquetamab for multiple myeloma after CAR T-cell therapy
This study tests a drug called talquetamab for people with multiple myeloma who have already had a type of immunotherapy called CAR T-cell therapy (ide-cel). The goal is to see if talquetamab can help control the cancer after the CAR T cells have had time to work.
Basking Ridge, New JerseyAges 18 years+ - NCT06409767Recruiting
Early warning system for blood cancer patients on chemo or transplant
This study tests whether a special early warning system can help doctors spot problems sooner in people with blood cancers who are getting strong chemo or a stem cell transplant. The goal is to improve outcomes by catching complications early.
AmiensAges 18 years+ - NCT06483048RecruitingPhase 1
MUC1-targeted T cells for relapsed ovarian cancer
This trial tests a new treatment using your own immune cells, modified to target a protein called MUC1 on ovarian cancer cells. It is for people with ovarian cancer that has come back or is resistant to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06990087RecruitingPhase 2
T-cell therapy for progressive multifocal leukoencephalopathy (PML)
This trial tests a T-cell therapy for people with PML, a rare brain infection. It aims to boost your immune system to fight the virus causing PML. You may be eligible if you have PML not caused by HIV, natalizumab, or certain recent treatments.
München, BavariaAges 18 years+ - NCT06993675RecruitingPhase 2
T-cell therapy for MRD in newly diagnosed myeloma patients after transplant
This trial tests two drugs (talquetamab and teclistamab) to see if they can eliminate remaining cancer cells in newly diagnosed myeloma patients who have already had a stem cell transplant. It may be an option if you have minimal residual disease (MRD) and a good response to initial treatment.
New Haven, ConnecticutAges 18 years+
Hear when a new T-cell Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t-cell leukemia?
- Yes. Clin2 currently lists 189 recruiting t-cell leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t-cell leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t-cell leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.